Evidence map›Paper›PMID 31040844›Full record

ReviewFrontiers in immunology2019

The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology.

Vega Masignani, Mariagrazia Pizza, E Richard Moxon

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 158 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Antimicrobial Resistance: The Answers.British journal of biomedical science · 2026
    Review
  9. Article
  10. Review
  11. Development of a vaccine construct againstNAR genomics and bioinformatics · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Towards precision epitopes based vaccine againstBiochemistry and biophysics reports · 2025
    Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Vega MasignaniGSK Vaccines, Siena, Italy.
Mariagrazia PizzaGSK Vaccines, Siena, Italy.
E Richard MoxonDepartment of Pediatrics, Oxford University, Oxford, United Kingdom.
Toscana Life Sciences · ITUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The discovery of vaccine antigens through whole genome sequencing (WGS) contrasts with the classical hypothesis-driven laboratory-based analysis of microbes to identify components to elicit protective immunity. This radical change in scientific direction and action in vaccine research is captured in the term

Indexed as

AnimalsAntigens, BacterialComputational BiologyGenes, BacterialHumansMeningitis, MeningococcalMeningococcal VaccinesMiceNeisseria meningitidis, Serogroup BVaccines, SyntheticVaccinologyWhole Genome Sequencing4CMenB vaccineAntigens, BacterialMeningococcal VaccinesVaccines, Synthetic4CMenB vaccineantigenic variabilitycross protectionNeisseria meningitidis serogroup B (MenB)reverse vaccinologystrain coverage

Identifiers

PMID31040844
PMCPMC6477034
OpenAlexW2939055544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.